[go: up one dir, main page]

NO20090119L - Composition comprising controlled release nanoparticulated meloxicam and hydrocodone - Google Patents

Composition comprising controlled release nanoparticulated meloxicam and hydrocodone

Info

Publication number
NO20090119L
NO20090119L NO20090119A NO20090119A NO20090119L NO 20090119 L NO20090119 L NO 20090119L NO 20090119 A NO20090119 A NO 20090119A NO 20090119 A NO20090119 A NO 20090119A NO 20090119 L NO20090119 L NO 20090119L
Authority
NO
Norway
Prior art keywords
hydrocodone
composition
meloxicam
nanoparticulated
combination
Prior art date
Application number
NO20090119A
Other languages
Norwegian (no)
Inventor
Gurvinder Singh Rekhi
Gary Liversidge
Scott Jenkins
John Devane
Niall Fanning
Paul Stark
Original Assignee
Elan Pharma Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharma Int Ltd filed Critical Elan Pharma Int Ltd
Publication of NO20090119L publication Critical patent/NO20090119L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Oppfinnelsen gjelder sammensetninger som omfatter en nanopartikulær meloksikamsammensetning i kombinasjon med en multipartikulær hydrokodonsammensetning for modifisert frigivelse som etter administrering til en pasient tilfører et hydrokodon på en bimodal eller multimodal måte. Den multipartikulære sammensetningen for modifisert frigivelse omfatter en første bestanddel og minst en påfølgende bestanddel hvor den første bestanddelen omfatter en første populasjon av hydrokodonholdige partikler og den minst ene påfølgende bestanddelen omfatter en andre populasjon av hydrokodonholdige partikler, hvori kombinasjonen av bestanddelene gir en bimodal eller multimodal frigivelsesprofil. Oppfinnelsen gjelder også en fast oral doseringsform som omfatter en slik kombinasjonssammensetning.This invention relates to compositions comprising a nanoparticulate meloxicam composition in combination with a modified release multiparticulate hydrocodone composition which, upon administration to a patient, supplies a hydrocodone in a bimodal or multimodal manner. The modified release multiparticulate composition comprises a first component and at least one subsequent component wherein the first component comprises a first population of hydrocodone-containing particles and the at least one subsequent component comprises a second population of hydrocodone-containing particles, wherein the combination of the components provides a bimodal or multimodal release profile. . The invention also relates to a solid oral dosage form comprising such a combination composition.

NO20090119A 2006-06-23 2009-01-09 Composition comprising controlled release nanoparticulated meloxicam and hydrocodone NO20090119L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81588406P 2006-06-23 2006-06-23
PCT/US2007/072054 WO2007150075A2 (en) 2006-06-23 2007-06-25 Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone

Publications (1)

Publication Number Publication Date
NO20090119L true NO20090119L (en) 2009-03-20

Family

ID=38834447

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090119A NO20090119L (en) 2006-06-23 2009-01-09 Composition comprising controlled release nanoparticulated meloxicam and hydrocodone

Country Status (11)

Country Link
EP (1) EP2032139A4 (en)
JP (1) JP2009541360A (en)
KR (1) KR20090023729A (en)
CN (1) CN101484169A (en)
AU (1) AU2007260822B2 (en)
CA (1) CA2660650A1 (en)
IL (1) IL196066A0 (en)
MX (1) MX2008016115A (en)
NO (1) NO20090119L (en)
WO (1) WO2007150075A2 (en)
ZA (1) ZA200810098B (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2957281A1 (en) 2001-09-21 2015-12-23 Egalet Ltd. Polymer release system
WO2003024430A1 (en) 2001-09-21 2003-03-27 Egalet A/S Morphine polymer release system
DE602004031096D1 (en) 2003-03-26 2011-03-03 Egalet As MORPHINE SYSTEM WITH CONTROLLED RELEASE
AU2008258596B2 (en) 2007-06-04 2013-02-14 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
EP2393484A1 (en) 2009-02-06 2011-12-14 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
NZ595986A (en) 2009-04-24 2014-04-30 Iceutica Pty Ltd A novel formulation of indomethacin
CA2763456C (en) 2009-05-27 2017-10-24 Alkermes Pharma Ireland Limited Reduction of flake-like aggregation in nanoparticulate active agent compositions
CA2766179A1 (en) 2009-06-24 2010-12-29 Egalet Ltd. Controlled release formulations
DK2826467T3 (en) 2010-12-22 2017-10-16 Purdue Pharma Lp INCLUDED, MANIPULATION-PROPOSED SLOW-DELIVERY DOSAGE FORMS
PH12013501345A1 (en) 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
EP2586429A1 (en) * 2011-10-26 2013-05-01 Freund Pharmatec Ltd. Multi-unit drug delivery device for pulsatile or sustained release
CN103070906A (en) * 2011-12-08 2013-05-01 赵联华 Quality control method of injection composition for treating orthopedic diseases
KR101785414B1 (en) * 2011-12-29 2017-10-16 라보라토리오스 안드로마코 에스.에이. Vaginal ring including meloxicam and an agent for modulating the release of the active principle, which can be used as a continuous-use contraceptive in women
CA2877183A1 (en) 2012-07-06 2014-01-09 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
HK1218392A1 (en) 2013-02-05 2017-02-17 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
WO2021257784A1 (en) * 2020-06-18 2021-12-23 Verté Therapeutics, Llc Injectable meloxicam formulations
CN113181249B (en) * 2021-05-25 2022-06-14 重庆市畜牧科学院 Preparation method of traditional Chinese medicine sustained-release granules for resisting piglet diarrhea

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS49982B (en) * 1997-09-17 2008-09-29 Euro-Celtique S.A., SYNERGISTIC ANALGETIC COMBINATION OF ANALGETIC OPIATE AND CYCLOOOXYGENASE-2 INHIBITOR
RU2236847C2 (en) * 1998-11-02 2004-09-27 Илан Корпорейшн, Плк. Composition as multiple particles with modified release
JP4806507B2 (en) * 1999-10-29 2011-11-02 ユーロ−セルティーク エス．エイ． Controlled release hydrocodone formulation
US6716449B2 (en) * 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
CA2463495C (en) * 2001-10-12 2011-05-24 Elan Pharma International Ltd. Compositions having a combination of immediate release and controlled release characteristics
US8512727B2 (en) * 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations

Also Published As

Publication number Publication date
AU2007260822A1 (en) 2007-12-27
WO2007150075A3 (en) 2008-04-24
CN101484169A (en) 2009-07-15
WO2007150075A2 (en) 2007-12-27
AU2007260822B2 (en) 2012-07-05
MX2008016115A (en) 2009-01-20
KR20090023729A (en) 2009-03-05
EP2032139A2 (en) 2009-03-11
IL196066A0 (en) 2009-09-01
ZA200810098B (en) 2009-12-30
CA2660650A1 (en) 2007-12-27
EP2032139A4 (en) 2012-08-22
JP2009541360A (en) 2009-11-26

Similar Documents

Publication Publication Date Title
NO20090119L (en) Composition comprising controlled release nanoparticulated meloxicam and hydrocodone
NO20090158L (en) Composition comprising naproxen nanoparticles and controlled release hydrocarbon
CL2009000171A1 (en) Compounds derived from 1-oxa-3-azaspiro, antagonists of the neuropeptide y5 receptor y (npy); pharmaceutical composition comprising said compound; and use for the treatment of eating disorders, drinking disorders, obesity, and depression.
UA96308C2 (en) Glucagon receptor antagonist compounds, composition comprising such compounds and use thereof
CL2007003604A1 (en) Pharmaceutical composition for oral administration comprising the amorphous 17-aminogeldanamycin compound; and its use in the treatment of cancer.
CL2011001131A1 (en) Use of a formulation that serves to prepare a drug for an injection, which minimizes inflammation at the site of injection of an antibody, and where the formulation comprises a 2h7 antibody and variants of the antibody and polyvinylpyrrolidone (pvp)
ATE469895T1 (en) CGRP RECEPTOR ANTAGONISTS
NO20064054L (en) Therapeutic combinations of atypical antipsychotics with corticotropin release factor antagonists
CL2007003299A1 (en) COMPOUNDS DERIVED FROM MACROCICLES, INHIBITORS OF THE HEPATITIS C VIRUS; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF HEPATITIS C.
NO20070785L (en) Compositions for the delivery of heavily water-soluble drugs.
CL2007003202A1 (en) COMPOUNDS DERIVED FROM ESPIROINDOLINONA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF CELL PROLIFERATION DISORDERS.
CL2007002658A1 (en) COMPOUNDS DERIVED FROM PURINA; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF AN INFLAMMATORY OR OBSTRUCTIVE DISEASE OF THE RESPIRATORY ROADS.
CR20110110A (en) PHARMACEUTICAL COMPOSITION
UA98839C2 (en) N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
CL2008001049A1 (en) COMPOUNDS DERIVED FROM SUBSTITUTED BENZAMIDS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF DIABETES, INTOLERANCE TO GLUCOSE, DISLIPIDEMIA, HYPERTENSION, OBESITY.
ECSP099634A (en) USED PIRIDAZINONE DERIVATIVES AS INHIBITORS OF GLUCANO SINTASA
TR201902010T4 (en) Delivery device for oral administration of an agent.
UA94942C2 (en) Dpp iv inhibitor formulations
CL2007002649A1 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES 2- [6- (3-AMINO-PIPERIDIN-1-IL) -3-METIL-2,4-DIOXO-3,4-DIHIDRO-2H-PIRIMIDIN-1-ILMETIL] -4-FLUORO- BENZONITRILE; AND USE FOR THE TREATMENT OF DIABETES.
CL2011000691A1 (en) Compounds derived from substituted nicotinamide; pharmaceutical composition that includes them; use for the treatment and / or prevention of cancer, infections, inflammatory and autoimmune diseases.
CL2010000188A1 (en) A method for treating an infection in a subject comprising the administration of 9 - [(2,2-dimethyl-propylamino) -methyl] -minocycline or a salt thereof; pharmaceutical composition comprising said compound; and its use.
CL2007002578A1 (en) COMPOUNDS DERIVED FROM N- (1-FTALAZIN-1-IL-PIPERIDIN-4-IL) -AMIDAS; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT AND PREVENTION OF FERTILITY, OSTEOPOROSIS AND CANCER DISORDERS.
WO2007095091A3 (en) Oral delivery of therapeutic agents using tight junction agonists
EA201070689A1 (en) COMPOSITION FOR PERSONAL CARE
CL2008000059A1 (en) COMPOUNDS DERIVED FROM ESPIROPIPERIDINA-GLICINAMIDA; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF HYPERTENSION, DISMENORREA, CHRONIC CARDIAC FAILURE, ANXIETY, T

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application